aa

In moderate to severe COVID-19 early in illness, Casirivimab and Imdevimab (REGEN-COV™) may be considered in settings where it is possible to obtain an antibody test quickly and this drug in the required dose of 8g is accessible, available and the prohibitive cost does not preclude its use.Hence we do not recommend its use in moderate and severeCOVID 19 infection in patients with detectable COVID-19 antibodies. However, Casirivimab and Imdevimab (REGEN- COV™) may be considered in a narrow subset of patients i.e., hospitalized COVID 19 patients requiring oxygen support, early in the illness with no detectable COVID-19 antibodies suggesting the lack of an immune response(Conditional recommendation).